Novartis joins legal action against unapproved copy of radioligand therapy

In the unprecedented move announced in the 2024-25 Mid-Year Economic and Fiscal Outlook, the copy recommended by the Medical Services Advisory Committee would be funded despite no evaluation or approval by the Therapeutic Goods Administration. …